New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
08:28 EDTAGN, REGNRegeneron compettive concerns overdone, says RW Baird
Baird believes Regeneron (REGN) investor concerns regarding Allergan's (AGN) DARPin Phase ll data are overdone as the firm believes approval would be roughly five years out. Baird said the market may be misinterpreting the molecule's half-life and that its potency may be similar at best to Regeneron's Elyea. Shares of Regeneron are Outperform rated with a $205 price target.
News For REGN;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
14:04 EDTREGNRegeneron price target raised to $500 from $450 at Argus
Subscribe for More Information
March 25, 2015
11:03 EDTREGNRegeneron confirms FDA approval of EYLEA
Subscribe for More Information
10:35 EDTREGNFDA approves expanded indication for Eylea
Subscribe for More Information
March 23, 2015
16:14 EDTAGNPershing Square liquidates stake in Allergan
Subscribe for More Information
09:03 EDTAGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:17 EDTREGNAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTREGNRegeneron initiated with a Buy at Chardan
Subscribe for More Information
March 17, 2015
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
March 16, 2015
18:38 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
17:19 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
10:22 EDTAGNEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
08:23 EDTREGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTREGNRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTREGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use